Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease

Khreish, Fadi; Rosar, Florian; Kratochwil, Clemens; Giesel, Frederik L.; Haberkorn, Uwe; Ezziddin, Samer

doi:10.1007/s00259-019-04623-x

Cited by 48 publications

(119 citation statements)

References 3 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Cancer-associated fibroblasts (CAFs) are important non-mutated cellular components of the tumor microenvironment modulating angiogenesis, cancer metastasis, and therapy responses [ 168 ]. CAFs express fibroblast activation protein (FAP) that can be targeted with 68 Ga-radiolabeled quinoline-based inhibitors of FAP (FAPI) [ 169 , 170 ]. 68 Ga-FAPI has shown promise in detecting metastasis of various cancer types, including PSMA-negative prostate cancer metastases [ 169 , 170 ].…”

Section: Other Radioligands and Targets In Prostate Cancer In Comparison With Psma Based Targetingmentioning

confidence: 99%

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond

Hyväkkä

Virtanen

Kemppainen

et al. 2021

Cancers

View full text Add to dashboard Cite

Prostate cancer is the second most common cancer type in men globally. Although the prognosis for localized prostate cancer is good, no curative treatments are available for metastatic disease. Better diagnostic methods could help target therapies and improve the outcome. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed on malignant prostate tumor cells and correlates with the aggressiveness of the disease. PSMA is a clinically validated target for positron emission tomography (PET) imaging-based diagnostics in prostate cancer, and during recent years several therapeutics have been developed based on PSMA expression and activity. The expression of PSMA in prostate cancer can be very heterogeneous and some metastases are negative for PSMA. Determinants that dictate clinical responses to PSMA-targeting therapeutics are not well known. Moreover, it is not clear how to manipulate PSMA expression for therapeutic purposes and develop rational treatment combinations. A deeper understanding of the biology behind the use of PSMA would help the development of theranostics with radiolabeled compounds and other PSMA-based therapeutic approaches. Along with PSMA several other targets have also been evaluated or are currently under investigation in preclinical or clinical settings in prostate cancer. Here we critically elaborate the biology and scientific rationale behind the use of PSMA and other targets in the detection and therapeutic targeting of metastatic prostate cancer.

show abstract

Section: Other Radioligands and Targets In Prostate Cancer In Comparison With Psma Based Targetingmentioning

confidence: 99%

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond

Hyväkkä

Virtanen

Kemppainen

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…General advances in imaging are increasingly revealing the limitations of bone scanning, particularly for modifying treatment outcomes and early detection of treatment response in cancers [ 50 – 52 ]. Recent PET tracers are promising for the application of PET in the initial evaluation of several oncologic diseases [ 53 , 54 ]. Since automated synthesis systems have increased the reliability, reproducibility and safety of radiopharmaceutical productions [ 55 – 57 ], the absence of PET services in Nigeria is largely due to the high cost of investment.…”

Section: Discussionmentioning

confidence: 99%

Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research

Orunmuyi¹,

Lawal²,

Omofuma³

et al. 2020

ecancer

View full text Add to dashboard Cite

Background: Nuclear medicine needs better integration into the Nigerian health system. To understand the relevant public health initiatives that will be required, this study assessed the pattern of nuclear medicine imaging services at the first nuclear medicine centre in Nigeria from January 2010 to December 2018. Methods: The data of consecutive nuclear medicine (NM) scans performed between 1st January 2010 and 31st December 2018 at the NM department in a tertiary hospital in Nigeria were extracted from patient records and analysed using SAS version 9.4 (SAS Institute, Cary, NC). The National Cancer Institute's Joinpoint software and QCIS (QGIS project) were used to estimate imaging trends and geographical spread of patients. Results: An average of 486 scans per year was performed during the study period. Patients travelled from 32 of Nigeria's 36 states, and the majority (65%) travelled more than 100 km to obtain NM scans. Bone scans accounted for 88.1% of the studies. The remainder were renal scintigraphy (7.3%), thyroid scans (2.5%), whole-body iodine scans (1.7%) and others (0.4%). Conclusions: NM in Nigeria appears underutilised. Furthermore, the studies to characterise the access gaps and implementation needs will contribute to the design of practical strategies to strengthen NM services in Nigeria.

show abstract

“…Combining aand b-emitters may improve these dual antitumor effects via short-range a-radiation to CAFs and mid-to long-range b-radiation to cancer cells. As another potential application, combining FAP-targeted with PSMA-targeted MRT may increase radiation doses in stroma-rich prostate cancer lesions (13,14).…”

Section: Why Is Fap-targeted Therapy Attractive?mentioning

confidence: 99%

FAP: The Next Billion Dollar Nuclear Theranostics Target?

Calais

2020

J Nucl Med

View full text Add to dashboard Cite

Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease

Cited by 48 publications

References 3 publications

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond

Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research

FAP: The Next Billion Dollar Nuclear Theranostics Target?

Contact Info

Product

Resources

About